
Mitchell Horwitz, MD, principal investigator and professor of medicine at the Duke Cancer Institute, discusses the results of a phase 3 study of omidubicel, which treats patients with hematologic malignancies in need of a bone marrow.
Mitchell Horwitz, MD, principal investigator and professor of medicine at the Duke Cancer Institute, discusses the results of a phase 3 study of omidubicel, which treats patients with hematologic malignancies in need of a bone marrow.
Researchers found no evidence that protection against COVID-19 reinfection declined within a 6-month follow-up period.
In addition to cardiotoxicity from cancer-related treatments, the researchers noted that obesity, cancer, and cardiovascular disease share some common risk factors.
Digital health products and solutions expand ways to guide prevention and treatment.
Caroline Carney, MD, MSc, FAPM, CPHQ, CMO of Magellan Health, discusses how pharmacists and other medical professionals can boost their brain health and keep a positive mindset while working during the pandemic.
Trust between a physician and pharmacist is essential to the overall quality of patient-centered care.
The plot clinical trial included 40 men and is believed to be the first published study to use progesterone to treat male COVID-19 patients whose lung functions have been compromised by the virus.
Farah Towfic, PharmD, MBA, director, CEO operations at US Pharmacopeia (USP), discusses USP’s release of an updated version of its COVID-19 Vaccine Handling Toolkit in response to feedback from independent pharmacies to mass vaccination clinics.
The COVID-19 pandemic significantly impacted pharmacy practice due to its role in supporting overwhelmed physicians, nurses, and other health care professionals who faced some of the immediate challenges of the crisis.
A new study published in The American Journal of Clinical Nutrition found that for colorectal cancer survivors, maintaining a stable body weight may hide a loss of muscle and the development of fatty deposits in their muscles, which resulted in a 40% higher risk of premature death.
Technology is essential, but not all solutions meet every goal or offer the same capabilities.
The FDA has approved the submission of a supplemental new drug application (sNDA) that expands the use of bupivacaine liposome injectable suspension to include patients aged 6 years and older for single-dose infiltration as a postsurgical local analgesia.
More than ever, confidence in objective, science-based data about therapeutics, such as the COVID-19 vaccine and other health care services, is a shared imperative across the pharmaceutical industry, health care communities, and the American public.
This vaccine rollout has become even more crucial for the US health care system, as new mutations of the coronavirus continue to emerge.
New results show that non-Hispanic Black patients with COVID-19 and type 1 diabetes have an additional risk of diabetic ketoacidosis beyond the risk of having diabetes or being of minority status.
Results from a phase 3 trial investigating the programmed cell death protein 1 inhibitor cemiplimab monotherapy compared to chemotherapy showed an overall survival benefit among patients previously treated with chemotherapy whose cervical cancer is recurrent or metastatic.
Electricity may slow the speed at which breast cancer cells spread through the body, and in some cases may stop them entirely, according to a new study published in Bioelectricity.
Following a review of the latest interim data released by AstraZeneca on its US phase 3 clinical trial assessing the 2-dose AZD1222 COVID-19 vaccine, the Data and Safety Monitoring Board (DSMB) expressed concern at the inclusion of what may have been outdated data.
Phase 3 clinical testing of a plant-derived COVID-19 vaccine candidate in combination with a pandemic adjuvant commenced following approval to proceed with participant enrollment from regulatory authorities in both Canada and the United States.
Investigators found a statistically significant improvement in both overall survival and progression-free survival for patients who received pembrolizumab with chemotherapy.
Low doses of propylparaben–a chemical preservative found in food, drugs, and cosmetics–can alter pregnancy-related changes in the breast in ways that may lessen the protection against breast cancer normally conveyed by pregnancy hormones.
The IGCS Mentorship and Training Program seeks to provide training and education to regions without formal training programs in gynecologic oncology.
Clinicians have been searching for accurate, reliable, non-invasive diagnostic tools to differentiate early stage, less dangerous, and more treatable stages of the disease from the aggressive, high-grade and likely-to-spread forms.
The independent data safety monitoring board conducted a specific review of thrombotic events related to AstraZeneca’s COVID-19 vaccine and found no increased risk.
The findings reveal a unique mechanism for C.diff survival in the human gut and suggest novel strategies for weakening its defenses, according to the study authors.
In a recent interview with Pharmacy Times, Raj Desai, PharmD, MBA, discussed a recent COVID-19 vaccination event at Houston Methodist Sugar Land Hospital, where he is the director of pharmacy.
Nine in 10 patients with multiple sclerosis who received the medication did not have worsening of 3-month disability, and ponesimod showed a numerical benefit in delaying disability progression.
Language barriers can present a major obstacle to patient involvement in cancer care, although clinicians recommended several potential strategies to help patients who speak different languages.
The study also found that women with chest pain were more likely than men to wait more than 12 hours before seeking medical help.
Results of clinical trials have shown that a nitric oxide nasal spray is both a safe and effective antiviral treatment to prevent COVID-19 transmission and symptom duration, as well as reduce symptom severity and damage in those already infected.